{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:16:27Z","timestamp":1785762987889,"version":"3.56.0"},"reference-count":92,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Russian Ministry of Science and High Education","award":["05.604.21.0234"],"award-info":[{"award-number":["05.604.21.0234"]}]},{"name":"Russian Ministry of Science and High Education","award":["RFMEFI60419X0234"],"award-info":[{"award-number":["RFMEFI60419X0234"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Assessments of breast cancer (BC) risk in carriers of pathogenic variants identified by gene panel testing in different populations are highly in demand worldwide. We performed target sequencing of 78 genes involved in DNA repair in 860 females with BC and 520 age- and family history-matched controls from Central Russia. Among BC patients, 562\/860 (65.3%) were aged 50 years or less at the time of diagnosis. In total, 190\/860 (22%) BC patients were carriers of 198 pathogenic\/likely pathogenic (P\/LP) variants in 30 genes, while among controls, 32\/520 (6.2%) carriers of P\/LP variants in 17 genes were identified. The odds ratio [95% confidence interval] was 16.3 [4.0\u201366.7] for BRCA1; 12.0 [2.9\u201345.9] for BRCA2; and 7.3 [0.9\u201356.7] for ATM (p &lt; 0.05). Previously undescribed BRCA1\/2, ATM, and PALB2 variants, as well as novel recurrent mutations, were identified. The contribution to BC susceptibility of truncating variants in the genes BARD1, RAD50, RAD51C, NBEAL1 (p. E1155*), and XRCC2 (p. P32fs) was evaluated. The BLM, NBN, and MUTYH genes did not demonstrate associations with BC risk. Finding deleterious mutations in BC patients is important for diagnosis and management; in controls, it opens up the possibility of prevention and early diagnostics.<\/jats:p>","DOI":"10.3390\/ijms252312640","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T05:21:32Z","timestamp":1732512092000},"page":"12640","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High- and Moderate-Risk Variants Among Breast Cancer Patients and Healthy Donors Enrolled in Multigene Panel Testing in a Population of Central Russia"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-9203","authenticated-orcid":false,"given":"Syuykum","family":"Shumilova","sequence":"first","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, the Russian Academy of Sciences, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Danishevich","sequence":"additional","affiliation":[{"name":"SBHI Moscow Clinical Scientific Center named after Loginov of Moscow Healthcare Department, 111123 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0673-3590","authenticated-orcid":false,"given":"Sergey","family":"Nikolaev","sequence":"additional","affiliation":[{"name":"SBHI Moscow Clinical Scientific Center named after Loginov of Moscow Healthcare Department, 111123 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6493-8378","authenticated-orcid":false,"given":"George","family":"Krasnov","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, the Russian Academy of Sciences, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8434-5916","authenticated-orcid":false,"given":"Anna","family":"Ikonnikova","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, the Russian Academy of Sciences, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darya","family":"Isaeva","sequence":"additional","affiliation":[{"name":"SBHI Moscow Clinical Scientific Center named after Loginov of Moscow Healthcare Department, 111123 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Surzhikov","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, the Russian Academy of Sciences, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zasedatelev","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, the Russian Academy of Sciences, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Bodunova","sequence":"additional","affiliation":[{"name":"SBHI Moscow Clinical Scientific Center named after Loginov of Moscow Healthcare Department, 111123 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2642-4202","authenticated-orcid":false,"given":"Tatiana","family":"Nasedkina","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, the Russian Academy of Sciences, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.2270482","article-title":"Linkage of early-onset familial breast cancer to chromosome 17q21","volume":"250","author":"Hall","year":"1990","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/gim.2016.31","article-title":"Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model","volume":"18","author":"Lee","year":"2016","journal-title":"Genet. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1245\/s10434-020-09158-2","article-title":"Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations","volume":"28","author":"Bergstrom","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients with Breast Cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2504","DOI":"10.1002\/mgg3.2504","article-title":"Hereditary breast cancer next-generation sequencing panel evaluation in the south region of Brazil: A novel BRCA2 candidate pathogenic variant is reported","volume":"12","author":"Duarte","year":"2024","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tsaousis, G.N., Papadopoulou, E., Apessos, A., Agiannitopoulos, K., Pepe, G., Kampouri, S., Diamantopoulos, N., Floros, T., Iosifidou, R., and Katopodi, O. (2019). Analysis of hereditary cancer syndromes by using a panel of genes: Novel and multiple pathogenic mutations. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5756-4"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Guindalini, R.S.C., Viana, D.V., Kitajima, J.P.F.W., Rocha, V.M., L\u00f3pez, R.V.M., Zheng, Y., Freitas, \u00c9., Monteiro, F.P.M., Valim, A., and Schlesinger, D. (2022). Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-07383-1"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bilyalov, A., Danishevich, A., Nikolaev, S., Vorobyov, N., Abramov, I., Pismennaya, E., Terehova, S., Kosilova, Y., Primak, A., and Stanoevich, U. (2023). Novel Pathogenic Variants in Hereditary Cancer Syndromes in a Highly Heterogeneous Cohort of Patients: Insights from Multigene Analysis. Cancers, 16.","DOI":"10.3390\/cancers16010085"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/jmedgenet-2018-105606","article-title":"Screening of BRCA1\/2 deep intronic regions by targeted gene sequencing identifies the first germline BRCA1 variant causing pseudoexon activation in a patient with breast\/ovarian cancer","volume":"56","author":"Montalban","year":"2019","journal-title":"J. Med. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100235","DOI":"10.1016\/j.esmoop.2021.100235","article-title":"Impact of deleterious variants in other genes beyond BRCA1\/2 detected in breast\/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: Looking over the hedge","volume":"6","author":"Bono","year":"2021","journal-title":"ESMO Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","article-title":"Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment","volume":"32","author":"Kurian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","article-title":"Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment","volume":"1","author":"Desmond","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gim.2014.176","article-title":"Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1\/2-negative patients with early-onset breast cancer","volume":"17","author":"Maxwell","year":"2015","journal-title":"Genet. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/jmedgenet-2019-106403","article-title":"Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel","volume":"57","author":"Sopik","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing","volume":"110","author":"Shimelis","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41436-019-0633-8","article-title":"A clinical guide to hereditary cancer panel testing: Evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients","volume":"22","author":"LaDuca","year":"2020","journal-title":"Genet. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cam4.1376","article-title":"Gene panel testing of 5589 BRCA1\/2-negative index patients with breast cancer in a routine diagnostic setting: Results of the German Consortium for Hereditary Breast and Ovarian Cancer","volume":"7","author":"Hauke","year":"2018","journal-title":"Cancer Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A Population-Based Study of Genes Previously Implicated in Breast Cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Breast Cancer Association Consortium, Dorling, L., Carvalho, S., Allen, J., Gonz\u00e1lez-Neira, A., Luccarini, C., Wahlstr\u00f6m, C., Pooley, K.A., Parsons, M.T., and Fortuno, C. (2021). Breast Cancer Risk Genes\u2014Association Analysis in More than 113,000 Women. N. Engl. J. Med., 384, 428\u2013439.","DOI":"10.1056\/NEJMoa1913948"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41523-021-00360-3","article-title":"Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing","volume":"7","author":"Southey","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13053-021-00169-y","article-title":"BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: Update","volume":"19","author":"Savanevich","year":"2021","journal-title":"Hered Cancer Clin. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/ijc.32492","article-title":"The spectrum of mutations predisposing to familial breast cancer in Poland","volume":"145","author":"Cybulski","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10689-007-9120-5","article-title":"Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia","volume":"6","author":"Sokolenko","year":"2007","journal-title":"Fam. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1134\/S0026893314020149","article-title":"Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips","volume":"48","author":"Nasedkina","year":"2014","journal-title":"Mol. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-020-05827-8","article-title":"Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients","volume":"184","author":"Sokolenko","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s11033-022-08215-1","article-title":"Germline variants associated with breast cancer in Khakass women of North Asia","volume":"50","author":"Gervas","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-023-07135-3","article-title":"Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus","volume":"203","author":"Sokolenko","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.31557\/APJCP.2022.23.6.2027","article-title":"Pathogenicity Reclassification of Genetic Variants Related to Early-Onset Breast Cancer among Women of Mongoloid Origin","volume":"23","author":"Gervas","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Pintican, R.M., Chiorean, A., Duma, M., Feier, D., Szep, M., Eniu, D., Goidescu, I., and Dudea, S. (2022). Are Mutation Carrier Patients Different from Non-Carrier Patients? Genetic, Pathology, and US Features of Patients with Breast Cancer. Cancers, 14.","DOI":"10.3390\/cancers14112759"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1002\/humu.23842","article-title":"The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries","volume":"40","author":"Laitman","year":"2019","journal-title":"Hum. Mutat."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Patruno, M., De Summa, S., Resta, N., Caputo, M., Costanzo, S., Digennaro, M., Pilato, B., Bagnulo, R., Pantaleo, A., and Simone, C. (2021). Spectrum of Germline Pathogenic Variants in BRCA1\/2 Genes in the Apulian Southern Italy Population: Geographic Distribution and Evidence for Targeted Genetic Testing. Cancers, 13.","DOI":"10.3390\/cancers13184714"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gomes, R., Soares, B.L., Felicio, P.S., Michelli, R., Netto, C.B., Alemar, B., Ashton-Prolla, P., Palmero, E.I., and Moreira, M.\u00c2.M. (2020). Haplotypic characterization of BRCA1 c.5266dupC, the prevailing mutation in Brazilian hereditary breast\/ovarian cancer. Genet. Mol. Biol., 43.","DOI":"10.1590\/\/1678-4685-gmb-2019-0072"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jamaoncol.2015.28","article-title":"Multigene Panel Testing in Oncology Practice: How Should We Respond?","volume":"1","author":"Kurian","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Yamamoto, H., and Hirasawa, A. (2021). Homologous Recombination Deficiencies and Hereditary Tumors. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010348"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Creeden, J.F., Nanavaty, N.S., Einloth, K.R., Gillman, C.E., Stanbery, L., Hamouda, D.M., Dworkin, L., and Nemunaitis, J. (2021). Homologous recombination proficiency in ovarian and breast cancer patients. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08863-9"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.molmed.2017.10.007","article-title":"Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer","volume":"23","author":"Connor","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Fang, C.B., Wu, H.T., Zhang, M.L., Liu, J., and Zhang, G.J. (2020). Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00160"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/s41436-018-0005-9","article-title":"Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families","volume":"20","author":"Harter","year":"2018","journal-title":"Genet. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kowalik, A., Sio\u0142ek, M., Kopczy\u0144ski, J., Krawiec, K., Kalisz, J., Zi\u0119ba, S., Kozak-Klonowska, B., Wypi\u00f3rkiewicz, E., Furma\u0144czyk, J., and Nowak-Ozimek, E. (2018). BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1\/2 next-generation sequencing study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0201086"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-018-4887-7","article-title":"The yield of full BRCA1\/2 genotyping in Israeli high-risk breast\/ovarian cancer patients who do not carry the predominant mutations","volume":"172","author":"Ginzach","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-022-06782-2","article-title":"A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia","volume":"197","author":"Kechin","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mrfmmm.2018.12.005","article-title":"Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk","volume":"813","author":"Solodskikh","year":"2019","journal-title":"Mutat. Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Stegel, V., Krajc, M., Zgajnar, J., Teugels, E., De Gr\u00e8ve, J., Ho\u010devar, M., and Novakovi\u0107, S. (2011). The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. BMC Med. Genet., 12.","DOI":"10.1186\/1471-2350-12-9"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10549-017-4642-5","article-title":"BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia","volume":"168","author":"Jakimovska","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_51","first-page":"573","article-title":"The incidence and gene frequency of ataxia-telangiectasia in the United States","volume":"39","author":"Swift","year":"1986","journal-title":"Am. J. Hum. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ng1837","article-title":"ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles","volume":"38","author":"Renwick","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","article-title":"Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","volume":"147","author":"Lilyquist","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Moslemi, M., Moradi, Y., Dehghanbanadaki, H., Afkhami, H., Khaledi, M., Sedighimehr, N., Fathi, J., and Sohrabi, E. (2021). The association between ATM variants and risk of breast cancer: A systematic review and meta-analysis. BMC Cancer, 21.","DOI":"10.1186\/s12885-020-07749-6"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/gepi.21971","article-title":"Penetrance of ATM gene mutations in breast cancer: A meta-analysis of different measures of risk","volume":"40","author":"Marabelli","year":"2016","journal-title":"Genet. Epidemiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10549-008-0189-9","article-title":"A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer","volume":"118","author":"Bogdanova","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Podralska, M., Zi\u00f3\u0142kowska-Suchanek, I., \u017burawek, M., Dzikiewicz-Krawczyk, A., S\u0142omski, R., Nowak, J., Stembalska, A., Pesz, K., and Mosor, M. (2018). Genetic variants in ATM, H2AFX and MRE11 genes and susceptibility to breast cancer in the polish population. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4360-3"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2018.2956","article-title":"Association of Breast and Ovarian Cancers with Predisposition Genes Identified by Large-Scale Sequencing","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/ijc.32385","article-title":"Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer","volume":"145","author":"Kleiblova","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"104477","DOI":"10.1016\/j.ejmg.2022.104477","article-title":"Spectrum and frequency of CHEK2 variants in breast cancer affected and general population in the Baltic states region, initial results and literature review","volume":"65","author":"Pavlovica","year":"2022","journal-title":"Eur. J. Med. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/1055-9965.EPI-08-0416","article-title":"Family history, genetic testing, and clinical risk prediction: Pooled analysis of CHEK2 1100delC in 1828 bilateral breast cancers and 7030 controls","volume":"18","author":"Fletcher","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1200\/JCO.2012.42.7336","article-title":"CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer","volume":"30","author":"Weischer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"djv214","DOI":"10.1093\/jnci\/djv214","article-title":"Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women with Ovarian Cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/ijc.31921","article-title":"Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing","volume":"144","author":"Girard","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-011-1403-8","article-title":"Cancer predisposing BARD1 mutations in breast-ovarian cancer families","volume":"131","author":"Ratajska","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10689-017-0050-6","article-title":"Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine","volume":"17","author":"Myszka","year":"2018","journal-title":"Fam. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jmedgenet-2016-103839","article-title":"PALB2, CHEK2 and ATM rare variants and cancer risk: Data from COGS","volume":"53","author":"Southey","year":"2016","journal-title":"J. Med. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1007\/s13277-013-0830-z","article-title":"Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk","volume":"34","author":"Zhang","year":"2013","journal-title":"Tumour Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2174\/1568009623666230418101511","article-title":"RAD50 Deficient in a Breast Cancer Model Predicts Sensitivity to PARP Inhibitors","volume":"23","author":"Ramos","year":"2023","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/ijc.31579","article-title":"RAD50 germline mutations are associated with poor survival in BRCA1\/2-negative breast cancer patients","volume":"143","author":"Fan","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Del Valle, J., Rofes, P., Moreno-Cabrera, J.M., L\u00f3pez-D\u00f3riga, A., Belhadj, S., Vargas-Parra, G., Teul\u00e9, \u00c0., Cuesta, R., and Mu\u00f1oz, X. (2020). Exploring the Role of Mutations in Fanconi Anemia Genes in Hereditary Cancer Patients. Cancers, 12.","DOI":"10.3390\/cancers12040829"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/humu.20625","article-title":"Genetic subtyping of Fanconi anemia by comprehensive mutation screening","volume":"29","author":"Ameziane","year":"2008","journal-title":"Hum Mutat."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Shah, S., Kim, Y., Ostrovnaya, I., Murali, R., Schrader, K.A., Lach, F.P., Sarrel, K., Rau-Murthy, R., Hansen, N., and Zhang, L. (2013). Assessment of SLX4 Mutations in Hereditary Breast Cancers. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066961"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/jnci\/djaa030","article-title":"Ovarian and Breast Cancer Risks Associated with Pathogenic Variants in RAD51C and RAD51D","volume":"112","author":"Yang","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat Genet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/jmedgenet-2017-104588","article-title":"Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks","volume":"54","author":"Decker","year":"2017","journal-title":"J. Med. Genet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10549-019-05415-5","article-title":"Polish Hereditary Breast Cancer Consortium. Inherited variants in XRCC2 and the risk of breast cancer","volume":"178","author":"Rusak","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3389\/fgene.2019.01005","article-title":"Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer","volume":"18","author":"Glentis","year":"2019","journal-title":"Front. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1007\/s00018-003-3053-4","article-title":"Human MutY: Gene structure, protein functions and interactions, and role in carcinogenesis","volume":"60","author":"Parker","year":"2003","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/ejhg.2012.309","article-title":"MUTYH-associated polyposis (MAP): Evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events","volume":"22","author":"Aretz","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Nunziato, M., Di Maggio, F., Pensabene, M., Esposito, M.V., Starnone, F., De Angelis, C., Calabrese, A., D\u2019Aiuto, M., Botti, G., and De Placido, S. (2022). Multi-gene panel testing increases germline predisposing mutations\u2019 detection in a cohort of breast\/ovarian cancer patients from Southern Italy. Front. Med., 9.","DOI":"10.3389\/fmed.2022.894358"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Lintas, C., Canalis, B., Azzar\u00e0, A., Sabarese, G., Perrone, G., and Gurrieri, F. (2024). Exploring the Role of the MUTYH Gene in Breast, Ovarian and Endometrial Cancer. Genes, 15.","DOI":"10.3390\/genes15050554"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s13277-013-1256-3","article-title":"XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: A meta-analysis","volume":"35","author":"Yan","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Rump, A., Benet-Pages, A., Schubert, S., Kuhlmann, J.D., Janavi\u010dius, R., Mach\u00e1\u010dkov\u00e1, E., Foretov\u00e1, L., Kleibl, Z., Lhota, F., and Zemankova, P. (2016). Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer. PLoS Genet., 12.","DOI":"10.1371\/journal.pgen.1006248"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41436-020-0753-1","article-title":"Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer","volume":"22","author":"Clark","year":"2020","journal-title":"Genet. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/gim.2015.75","article-title":"POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and\/or polyposis: Review of reported cases and recommendations for genetic testing and surveillance","volume":"18","author":"Bellido","year":"2016","journal-title":"Genet. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1054\/bjoc.2000.1248","article-title":"Association of the I1307K APC mutation with hereditary and sporadic breast\/ovarian cancer: More questions than answers","volume":"83","author":"Patael","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ijc.32106","article-title":"Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy","volume":"145","author":"Rizzolo","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1148\/rg.2020190181","article-title":"Genetic Testing and Screening Recommendations for Patients with Hereditary Breast Cancer","volume":"40","author":"Bharucha","year":"2020","journal-title":"Radiographics"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Ye, J., Coulouris, G., Zaretskaya, I., Cutcutache, I., Rozen, S., and Madden, T.L. (2012). Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction. BMC Bioinform., 13.","DOI":"10.1186\/1471-2105-13-134"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/23\/12640\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:38:53Z","timestamp":1760114333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/23\/12640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":92,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ijms252312640"],"URL":"https:\/\/doi.org\/10.3390\/ijms252312640","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}